Euroapi SAS (EAPI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Euroapi SAS (EAPI) has a cash flow conversion efficiency ratio of -0.139x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-65.50 Million ≈ $-76.58 Million USD) by net assets (€470.40 Million ≈ $549.95 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see EAPI company net worth for the company's overall valuation and market capitalisation.
Euroapi SAS - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Euroapi SAS's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Euroapi SAS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Euroapi SAS ranked by their cash flow conversion efficiency. Explore EAPI cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Panasonic Manufacture Malaysia
KLSE:3719
|
0.002x |
|
ATHOS IMMO (IJM.SG)
STU:IJM
|
N/A |
|
The Naga Group AG
XETRA:N4G
|
0.002x |
|
Ekadharma International Tbk
JK:EKAD
|
0.026x |
|
Helius Medical Technologies Inc Class A
NASDAQ:HSDT
|
0.027x |
|
Morn Sun Feed Mill Corp
TWO:1240
|
0.009x |
|
ST Dupont
PA:DPT
|
-0.078x |
|
Articore Group Ltd
AU:ATG
|
-0.437x |
Annual Cash Flow Conversion Efficiency for Euroapi SAS (2019–2025)
The table below shows the annual cash flow conversion efficiency of Euroapi SAS from 2019 to 2025. View latest Euroapi SAS stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €788.00 Million ≈ $921.25 Million |
€125.50 Million ≈ $146.72 Million |
0.159x | +27.45% |
| 2024-12-31 | €983.50 Million ≈ $1.15 Billion |
€122.90 Million ≈ $143.68 Million |
0.125x | +2173.08% |
| 2023-12-31 | €927.70 Million ≈ $1.08 Billion |
€5.10 Million ≈ $5.96 Million |
0.005x | -86.38% |
| 2022-12-31 | €1.11 Billion ≈ $1.30 Billion |
€44.80 Million ≈ $52.38 Million |
0.040x | -42.91% |
| 2021-12-31 | €1.01 Billion ≈ $1.18 Billion |
€71.50 Million ≈ $83.59 Million |
0.071x | -27.75% |
| 2020-12-31 | €989.40 Million ≈ $1.16 Billion |
€96.80 Million ≈ $113.17 Million |
0.098x | +185.41% |
| 2019-12-31 | €1.02 Billion ≈ $1.19 Billion |
€34.90 Million ≈ $40.80 Million |
0.034x | -- |
About Euroapi SAS
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that use solid phase chemistry; … Read more